Full Press Release Details
Reports 2025 Financial Results and Provides Business Update
Highlighting Significant Progress with Pivotal Phase 3 Study
is the first frontline immunotherapy to demonstrate the potential for a clinically meaningful overall survival benefit in women newly
diagnosed with advanced ovarian cancer
Phase 2 clinical data show continued median overall survival improvement with IMNN-001
in the OVATION 3 Study, IMUNON's Phase 3 pivotal trial for IMNN-001, remains ahead of plan supported by continued strong interest
from principal investigators and the medical community
to hold conference call today at 11:00 a.m. EDT
N.J., March 31, 2026 (GLOBE NEWSWIRE) - IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in late-stage development
with its DNA-mediated immunotherapy, today reported financial results for the year ended December 31, 2025, and highlighted recent business
updates including progress in advancing Phase 3 clinical development of its lead candidate IMNN-001 in newly diagnosed advanced ovarian
continues to make significant progress in advancing IMNN-001, a potential breakthrough for women with newly diagnosed advanced ovarian
cancer," said Stacy Lindborg, Ph.D., president and chief executive officer of IMUNON. "A final data assessment of
the Phase 2 OVATION 2 Study indicates that treatment with IMNN-001 was associated with an overall survival benefit of more than a year
in patients treated with IMNN-001 plus chemotherapy and more than two years in women also receiving PARP inhibitors as part of maintenance
survival data results from the Phase 2 OVATION 2 Study, coupled with compelling interim results
from our MRD study and a clear regulatory path in Phase 3, position IMNN-001 with the potential to deliver transformative impact on ovarian
cancer treatment. These new results showing continued improvements in overall survival are especially exciting given that there
have been virtually no advances in frontline standard of care for women newly diagnosed with ovarian cancer in the last 35 years,"
Dr. Lindborg continued.
Phase 2 OVATION 2 Study Data Show Continued Overall Survival Improvement with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian
Cancer - On March 25, 2026, the Company announced final data from the completed Phase 2 OVATION 2 clinical trial evaluating
IMNN-001 in combination with standard of care (SoC) neoadjuvant and adjuvant chemotherapy (N/ACT) in 112 women with newly diagnosed advanced
ovarian cancer. IMUNON previously reported a median 11.1 month increase in overall survival (40.5 vs. 29.4 months) in the IMNN-001 treatment
arm compared to SoC chemotherapy alone. Following the most recent data assessment, the Company reported a median 14.7 month increase
in overall survival (45.1 vs. 30.4 months) in women in the IMNN-001 treatment arm compared to SoC alone, demonstrating continuous improvement
in overall survival (3.6 delta). In addition, the new IMNN-001 data showed that women treated with IMNN-001 and SoC chemotherapy plus
poly ADP-ribose polymerase (PARP) inhibitors as part of maintenance therapy achieved a median increase in overall survival of 24.2 months
(65.6 vs. 41.4 months) compared to SoC chemotherapy alone.
with these new efficacy results, IMNN-001 continued to show a highly favorable safety and tolerability profile, further reinforcing the
potential of this IL-12 immunotherapy to represent a landmark advance in treatment of this disease.
Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer - On November
10, 2025, the Company hosted an R&D Day, providing updates on new IMNN-001 data and discussing progress with the Phase 3 OVATION
3 Study and IMNN-001's potential role in transforming the treatment landscape for women with advanced ovarian cancer. Highlights
from the R&D Day are summarized below.
from the Phase 2 OVATION 2 clinical trial:
| Broad impact observed with IMNN-001 treatment on important cancer-fighting cytokines, effectively turning the tumor microenvironment from "cold" to "hot" by activating both innate and adaptive immune systems, renewing the elusive promise of an immunotherapy for ovarian cancer. | ||
| Data reinforcing the highly favorable benefit-risk and safety profile of IMMN 001. | ||
| The remarkable median 13-month overall survival (OS) benefit observed with IMNN-001 plus standard of care (SoC) chemotherapy, an increase that is considered clinically meaningful compared to SoC alone. |
tolerability and translational insights from the Phase 2 minimal residual disease (MRD) study of IMNN-001:
| Rationale for the trial and the importance of frontline therapy as the best opportunity to achieve a cure for ovarian cancer. | ||
| New translational data that show IMNN-001 preferentially being taken up by macrophages within the peritoneal fluid and tumor tissue, which then induces a robust response and tumor microenvironment remodeling. | ||
| New data supporting the highly favorable benefit-risk and tolerability profile of IMNN-001. | ||
| The positive tolerability profile of IMNN-001, including in combination with SoC chemotherapy plus bevacizumab, and in the maintenance setting. |
2 and ongoing Phase 3 trial designs, and the strength of evidence for IMNN-001 from a statistical perspective:
| The well-precedented nature of the Phase 3 trial design, which leverages an innovative, adaptive, event-driven approach aligned with prior successful oncology trials that resulted in full approval by the U.S. Food and Drug Administration (FDA) based on an interim analysis of overall survival. | ||
| This foundation, supported by conservative power assumptions drawn from Phase 2 clinical data, strong simulation modeling and robust statistical properties, underpins the Phase 3 trial's high probability for success. |
data further demonstrating IMNN-001 shifted the balance in favor of immune stimulation, remodeling the tumor microenvironment in favor
of anti-tumor responses, which is established to be associated with better prognosis.
presentations from the R&D Day are available on the "Scientific Presentations" page of the IMUNON website at https://investors.imunon.com/scientific-presentations.
Data from Phase 2 OVATION 2 Study of IMNN-001 at SITC 40th Annual Meeting - On November 7, 2025, the Company presented translational
data from the Phase 2 OVATION 2 clinical trial of IMNN-001
at the Society for Immunotherapy of Cancer (SITC)
40th Annual Meeting, held on November 5-9, 2025, in National Harbor,
SITC poster presentation is available on the "Scientific Presentations" page of the IMUNON website at https://investors.imunon.com/scientific-presentations.
3 OVATION 3 Study of IMNN-001 in Advanced Ovarian Cancer at the ESMO Congress and the IGCS 2025 Annual Global Meeting - On
October 14, 2025, the Company announced that a trials-in-progress abstract on the ongoing Phase 3 OVATION 3 clinical trial of IMNN-001
were being presented at the European Society for Medical Oncology (ESMO) Congress 2025, held on October 17-21, 2025, in Berlin, Germany
with an encore presentation following at the 2025 Annual Global Meeting of the International Gynecologic Cancer Society (IGCS), held
on November 5-7, 2025, in Cape Town, South Africa. The poster presentations are available on the "Scientific Presentations"
page of the IMUNON website at https://investors.imunon.com/scientific-presentations.
DNA Vaccine Technology
DNA Technology Proof-of-Concept Data Presented in Platform Presentations at Leading Vaccine Conferences - On October 17, 2025,
the Company announced oral presentations highlighting IMNN-101, its proof-of-concept DNA plasmid vaccine based on the Company's
proprietary PlaCCine technology platform, including proof-of-concept clinical trial results at the following vaccine
| 5th Edition of International Vaccines Congress (IVC) Keynote Oral Presentation: A promising novel approach to DNA vaccines , presented on October 23, 2025 | ||
| 10th International Conference on Vaccine Research and Development Oral Presentation: Development of a PlaCCine DNA Technology for Safe, Effective and Durable Vaccines , presented on November 6, 2025 |
presentations described the unique design and composition of the PlaCCine technology and its differentiating features including a longer
duration of antigen expression, safety, and user compliance, and storage stability at workable temperatures (up to one year at 4 C
and one month at 37 C) in comparison to mRNA vaccines and other DNA vaccines requiring viruses or devices for delivery. The immunogenicity
of the PlaCCine technology was demonstrated against various pathogens in multiple species and animal models. These presentations also
demonstrated safety and immunogenicity of a PlaCCine based vaccine (IMNN-101) targeting a SARS-CoV-2 spike variant in healthy human participants
following intramuscular administration. Durable neutralizing antibody (Nab) responses from baseline at six months demonstrating vaccine
immunogenicity following a single dose in previously vaccinated or infected individuals with the SARS-CoV-2 underscore the significance
of the PlaCCine approach and support continued development in both naive populations using a prime and boost vaccination to determine
optimal benefits and in other infectious diseases.
has been shown to be safe and well tolerated, with no serious adverse effects reported. To advance the development and commercialization
of the PlaCCine platform in the prophylactic vaccine competitive landscape, IMUNON will require a strategic partnership(s) with a pharmaceutical
or biotechnology company.
Sharpens Focus on its Promising Pivotal Phase 3 Ovarian Cancer Study - On February 5, 2026, the Company announced a strategic
reorganization, the goal of which was to reduce operating expenses while supporting the Company's focused strategy to rapidly advance
the pivotal Phase 3 OVATION 3 clinical trial.
Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules - On December 30, 2025, the Company announced that
it entered into a securities purchase agreement for the purchase and sale of 1,939,114 shares of common stock (or pre-funded warrants
in-lieu thereof), together with warrants to purchase up to an aggregate of 1,939,114 shares of common stock. Each share of common stock
(or pre-funded warrant in-lieu thereof) was sold together with one warrant to purchase one share of common stock at a combined purchase
price of $3.61 (or $3.6099 per pre-funded warrant and warrant). The warrants have an exercise price of $3.482 per share, and became exercisable
immediately upon issuance, and will expire five years from the date of issuance. The offering closed on December 31, 2025.
RESULTS FOR THE YEAR ENDED DECEMBER 31, 2025
Management Continues to Focus on the Phase 3 OVATION 3 Study -
reported a net loss for 2025 of $14.5 million, or $6.83 per share, compared with a net loss of $18.6 million, or $16.94 per share, for
2024. Operating expenses were $14.7 million for 2025; a 23% decrease compared to 2024.
and development (R&D) expenses were $7.8 million for 2025; a 33% decrease compared to 2024. The decrease was due primarily to lower
costs associated with the OVATION 2 Study, the Phase 1 proof-of-concept PlaCCine DNA vaccine trial, and development of the PlaCCine DNA
vaccine technology platform, partially offset by start-up costs associated with the pivotal Phase 3 OVATION 3 Study.
and administrative (G&A) expenses were $6.9 million for 2025, a decrease of 8% compared to 2024. This decrease was primarily attributable
to headcount reductions and lower employee-related expenses.
cash used for operating activities was $13.9 million for full year 2025 compared with $18.9 million for full year 2024. Cash provided
by financing activities of $17.1 million for 2025 resulted from two offerings in May 2025 and December 2025 ($13.6 million) and sales
under the Company's at-the-market equity facility ($3.5 million).
of December 31, 2025, cash and cash equivalents were $8.8
Company will be hosting a conference call to review 2025 financial results and provide a business update today, March 31, 2026, at 11:00
a.m. EDT. To participate in the call, please dial 800-715-9871 (North America/Toll Free) or 646-307-1963 (U.S./Toll) and ask for the
IMUNON Year End 2025 Financial Results Call (Conference ID 4157104). A live webcast of the call will also be available here.
audio replay of the call will be available for 90 days and can be accessed at 800-770-2030 (U.S. and Canada/Toll Free), 609-800-9909
(U.S./Toll) or 647-362-9199 (Canada/Toll) using replay access code 4157104#.
is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body's natural